FDDNP Protocol for Visualizing Brain Proteinopathies to Assist in the Diagnosis of Persons With Suspected CTE and AD

Inclusion criteria for all participants Participants enrolling in the trial must meet all of the following criteria: * Participant may be male or female and of any race/ethnicity * Age 18 to 80 years at the time of study drug dosing * Female participants must be either surgically sterilized or post-menopausal, defined as at least one-year without menses as reported by the participant or have a negative serum pregnancy test * Participant or participant's legally acceptable representative (when appropriate) provides informed consent * Participant is capable of complying with study procedures * Participant is capable of communicating with study personnel * Participant is willing to undergo longitudinal follow-up at 1 and 2 years after the Imaging Visit * All participants will meet criteria for mild cognitive impairment (Petersen et al, 2014) or Mild Neurocognitive Disorder (APA, 2013): * Patient awareness of a memory problem, preferably confirmed by another person who knows the patient * Memory impairment detected with standard assessment tests * Ability to perform normal daily activities * For a broad definition of mild cognitive impairment, we also use guidelines to identify those with other mild cognitive impairment subtypes, including those with memory impairment and/or additional cognitive deficits (Winblad et al, 2004). The diagnosis will be corroborated by clinical judgment and include participants who score 1 standard deviation or more below the age-corrected norms bec…